LLY
Eli Lilly and Company
LLY has the edge over PFE overall, supported by stronger valuation and stronger modeled upside.
PFE
Pfizer Inc.
PFE trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PFE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
PFE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over PFE in the historical PE scenario, which offers more potential upside but is not a forecast.
PFE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $6.78 | -76% |
| Forward | 10x | $28.83 | — |
| Fair | 15x | $10.59 | -63% |
| Expensive | 24x | $16.53 | -43% |
| Current | 41x | $28.83 | — |
Historical ranges are pointers, not guarantees.
PFE's PE is in its expensive range at 41x. On analysts' estimates for next year's earnings, today's price would be 10x, in its cheap range.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PFE on the outlook, with more favorable earnings and revenue expectations.
PFE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PFE's profitability to improve, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PFE on earnings, with more consistent year-over-year improvement.
PFE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.83 | +304% |
| Q3 2026 | $0.70 | -59% |
| Q2 2026 | $0.76 | -60% |
| Q1 2026 | $1.31 | -5.1% |
| Q4 2025 | $1.36 | -3.5% |
| Q3 2025 | $1.72 | +129% |
| Q2 2025 | $1.88 | +$2.33 |
| Q1 2025 | $1.38 | +$1.43 |
| Q4 2024 | $1.41 | +281% |
PFE's earnings per share have fallen from their peak: $0.70 over the past year, against $5.47 in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PFE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PFE on profitability, with a higher operating margin.
PFE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.6B | -0.4% |
| Q2 2026 | $15B | +2.6% |
| Q1 2026 | $14.5B | +5.4% |
| Q4 2025 | $17.6B | -1.2% |
| Q3 2025 | $16.7B | -5.9% |
| Q2 2025 | $14.7B | +10% |
| Q1 2025 | $13.7B | -7.8% |
| Q4 2024 | $17.8B | +25% |
PFE's revenue fell from its 2022 peak and has held roughly level since: $16.6B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.4 points |
| Q2 2026 | -4.3% | -25 points |
| Q1 2026 | 22% | +1.6 points |
| Q4 2025 | -9.3% | -9.3 points |
| Q3 2025 | 20% | -6.6 points |
| Q2 2025 | 21% | +22 points |
| Q1 2025 | 20% | -2.7 points |
| Q4 2024 | -0.1% | +29 points |
PFE's operating margin was 20% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
PFE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +20% |
| Q2 2026 | $302M | +$1.5B |
| Q1 2026 | $2.2B | +23% |
| Q4 2025 | $4.5B | -22% |
| Q3 2025 | $4B | -34% |
| Q2 2025 | -$1.2B | +$1.2B |
| Q1 2025 | $1.8B | +359% |
| Q4 2024 | $5.8B | +38% |
PFE still generates free cash flow, though less than at its 2021 peak: $11.8B over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PFE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PFE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +52M shares |
| 1 year | +0.6% | +37M shares |
| 3 years | +1.9% | +105M shares |
| 5 years | +0.5% | +26M shares |
| Available history | -3.9% | -230M shares |
PFE has 5.8B diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $2B |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over PFE on leverage, with a lower net debt burden relative to earnings.
PFE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q2 2026 | 5.8x | High |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 4.3x | High |
| Q4 2024 | 4.2x | High |
PFE's net debt is about 5.7 years of its operating earnings (EBITDA), up from 3.8 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PFE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.8 | Neutral |
| Stochastic | 72.5 | Neutral |
PFE's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PFE PE vs Healthcare Sector
| Metric | PFE | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 59% above |
| PE % | 97 | 29 | 68 pts above |
PFE has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PFE on trend strength, trading above more of its moving averages.
PFE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 1.1% below |
| 20 week MA | $27.5 | 4.9% above |
| 50 week MA | $26.8 | 7.7% above |
| 100 week MA | $25.8 | 12% above |
| 200 week MA | $29.0 | 0.4% below |
PFE's trend is mixed: it's above three of its five weekly moving averages, and 0.4% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PFE on returns for 2026, with the stronger performance.
PFE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.3 | $37.3 | 0% |
| 2021 | $37.3 | $58.7 | +58% |
| 2022 | $58.7 | $51.8 | -12% |
| 2023 | $51.8 | $28.8 | -44% |
| 2024 | $28.8 | $26.6 | -7.5% |
| 2025 | $26.6 | $25.1 | -5.7% |
| 2026 YTD | $25.1 | $28.8 | +15% |
PFE has finished four years in a row lower, and it's up 15% so far in 2026.